Rheumatoid arthritis Trials in Vienna, Austria
Conditions / Rheumatoid arthritis / Vienna, Austria
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
48 total trials for this combination
Showing top 10 of 48 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01885078 | An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT02675426 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone | COMPLETED | PHASE3 |
| NCT03915964 | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | COMPLETED | PHASE4 |
| NCT01709578 | To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | COMPLETED | PHASE3 |
| NCT01331837 | A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors | COMPLETED | PHASE4 |
| NCT01521923 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01519791 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01061736 | Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients | COMPLETED | PHASE2/PHASE3 |
| NCT02706847 | A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs | COMPLETED | PHASE3 |
| NCT01007435 | A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis | COMPLETED | PHASE3 |